The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity
- 1 December 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Blood Coagulation & Fibrinolysis
- Vol. 20 (8), 627-634
- https://doi.org/10.1097/mbc.0b013e32832da1e3
Abstract
Fibrinolytic activity has been shown to be reduced in many vascular diseases, including hepatic veno-occlusive disease after stem cell transplantation, a microangiopathy characterized by sinusoidal endothelial cell injury. Defibrotide is a polydisperse oligonucleotide with antithrombotic, profibrinolytic, anti-ischemic, and antiadhesive properties. Numerous clinical studies have shown promising activity of defibrotide in the treatment and prevention of veno-occlusive disease, with minimal toxicity. In corollary laboratory studies, defibrotide has been shown to decrease plasminogen activator inhibitor-1, increase tissue plasminogen activator levels, and increase overall plasma fibrinolytic activity in patients. Plasmin, a potent and nonspecific serine protease, plays a pivotal role in fibrinolysis by virtue of its ability to effectively degrade fibrin clots. In this study, defibrotide increases the activity of plasmin in hydrolyzing its substrate in a dose-dependent and length-dependent manner. Similar concentration-dependent effects of defibrotide were observed when plasmin was generated by tissue plasminogen activator or urokinase activation of plasminogen. In contrast, defibrotide had no direct effect on the activation of plasminogen to plasmin. Defibrotide was also able to enhance the activity of plasmin in degrading fibrin clot formed from fibrinogen, plasminogen, and thrombin. This effect was also concentration-dependent and directly correlated with the enzymatic activity of plasmin. This study therefore demonstrates that defibrotide is capable of enhancing the activity of plasmin and so contributes to its fibrinolytic activity. Taken together, these results support the effect of defibrotide in restoring the fibrinolytic vascular phenotype, in microangiopathic conditions such as veno-occlusive disease.Keywords
This publication has 32 references indexed in Scilit:
- A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusionJournal of Thrombosis and Haemostasis, 2008
- Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of DefibrotideSeminars in Thrombosis and Hemostasis, 2007
- Fibrin clot structure in patients with end-stage renal diseaseThrombosis and Haemostasis, 2007
- Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno‐occlusive diseasePediatric Transplantation, 2006
- Binding of the COOH-terminal Lysine Residue of Streptokinase to Plasmin(ogen) Kringles Enhances Formation of the Streptokinase·Plasmin(ogen) Catalytic ComplexesPublished by Elsevier BV ,2006
- Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation proteinBlood, 2006
- A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI unitsJournal of Thrombosis and Haemostasis, 2004
- Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center studyBone Marrow Transplantation, 2000
- DefibrotideDrugs, 1993
- Studies on the Lysine-Binding Sites of Human Plasminogen. The Effect of Ligand Structure on the Binding of Lysine Analogs to PlasminogenEuropean Journal of Biochemistry, 1980